NorthWest Biotherapeutics Inc (NWBO)

[Dan88]

I have posted right after CVM failed to meet its primary endpoint the fundamental difference between CVM and NWBO, and also thought CVM's agent Multikine should be approved for its safety and efficaciousness on those patients who are rightfully excluded from chemo treatment.

Simply put, CVM's agent Multikine is an immune booster which does not kill cancer cell while NWBO's agent DCVax-L is not only a booster but more importantly a cancer killer. Loaded with patient specific antigens, DCVax-L seeks, locates and kills remaining cancer.

That's a huge difference in MOAs, besides CVM has repeatedly failed using the same agent on other cancer indications while DCVax-L has never failed (actually it is on its first trial in phase 3).

CVM has experienced endless pumping from its own CEO while NWBO has been eerily quiet for a long time; CVM raised a significant amount of funds just before the announcement while NWBO has been running on fumes waiting TLD announcement.